GRCE Grace Therapeutics, Inc.
USHealthcareAs of 2026-07-09 16:00
Why GRCE matters now
Grace Therapeutics, Inc. (GRCE) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.44 with -2.01% on the session and $39.7M in market capitalization; recent performance reads 1-month +10.70% and YTD -31.21%.
The latest financial table shown here is Q3 2026, with revenue of $0.00, net income of $-3.2M, and EPS of $-0.19. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -24.1%.
The latest indexable market news headline is "Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $4.00; recent insider activity includes DAVIS A BRIAN filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.61
P/S
0.00
EV/EBITDA
-1.19
DCF Value
$0.70
FCF Yield
-24.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-14.9%
ROA
-14.2%
ROIC
-25.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $0.00 | $-3.2M | $-0.19 |
| Q2 2026 | $0.00 | $-1.3M | $-0.08 |
| Q1 2026 | $0.00 | $-4.6M | $-0.29 |
| Q4 2025 | $0.00 | $905.7K | $0.06 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$4.00
Target (Median)
$4.00
Target Range
$4.00 - $4.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.36
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.